Acknowledgement
This research was supported by a grant (18172MFDS182) from the Ministry of Food & Drug Safety in 2018.
References
- Picanco-Castro V, Goncalves Pereira C, Swiech K, Ribeiro Malmegrim KC, Tadeu Covas D, Silveira Porto G. Emerging CAR T cell therapies: clinical landscape and patent technological routes. Hum Vaccin Immunother 2020;16:1424-1433 https://doi.org/10.1080/21645515.2019.1689744
- Laurencin CT, McClinton A. Regenerative cell-based therapies: cutting edge, bleeding edge, and off the edge. Regen Eng Transl Med 2020;6:78-89 https://doi.org/10.1007/s40883-020-00147-1
- Peng B, Ming Y, Yang C. Regulatory B cells: the cutting edge of immune tolerance in kidney transplantation. Cell Death Dis 2018;9:109
- Watanabe Y, Tsuchiya A, Terai S. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clin Mol Hepatol 2021;27:70-80 https://doi.org/10.3350/cmh.2020.0194
- Moll G, Ankrum JA, Kamhieh-Milz J, Bieback K, Ringden O, Volk HD, Geissler S, Reinke P. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med 2019;25:149-163 https://doi.org/10.1016/j.molmed.2018.12.006
- Golchin A, Farahany TZ. Biological products: cellular therapy and FDA approved products. Stem Cell Rev Rep 2019;15:166-175 https://doi.org/10.1007/s12015-018-9866-1
- Shukla V, Seoane-Vazquez E, Fawaz S, Brown L, Rodriguez- Monguio R. The landscape of cellular and gene therapy products: authorization, discontinuations, and cost. Hum Gene Ther Clin Dev 2019;30:102-113 https://doi.org/10.1089/humc.2018.201
- Xu J, Sim JW. Characteristics of corporate R&D investment in emerging markets: evidence from manufacturing industry in China and South Korea. Sustainability 2018;10:3002
- Bas TG, Oliu Castillo C. Biosimilars in developed and developing East and Southeast Asian countries: Japan, South Korea, and Malaysia-overview, evolution, and regulations assessment. Biomed Res Int 2016;2016:5910403
- Mendicino M, Fan Y, Griffin D, Gunter KC, Nichols K. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon. Cytotherapy 2019;21:699-724 https://doi.org/10.1016/j.jcyt.2019.04.002
- Herberts CA, Kwa MS, Hermsen HP. Risk factors in the development of stem cell therapy. J Transl Med 2011;9:29
- Izeta A, Herrera C, Mata R, Astori G, Giordano R, Hernandez C, Leyva L, Arias S, Oyonarte S, Carmona G, Cuende N. Cell-based product classification procedure: what can be done differently to improve decisions on borderline products? Cytotherapy 2016;18:809-815 https://doi.org/10.1016/j.jcyt.2016.03.292
- Therapeutic Goods Administration, Department of Health, Australian Government. Intended use: interpretation of homologous use Australian Regulatory Guidelines for Biologicals (ARGB). Version 1.0. Woden: Commonwealth of Australia; 2018.
- Schmidt C. FDA approves first cell therapy for wrinkle-free visage. Nat Biotechnol 2011;29:674-675 https://doi.org/10.1038/nbt0811-674
- Dunkin BS, Lattermann C. New and emerging techniques in cartilage repair: MACI. Oper Tech Sports Med 2013;21:100-107 https://doi.org/10.1053/j.otsm.2013.03.003
- Falanga V, Faria K, Bollenbach T. Bioengineered skin constructs. In: Lanza R, Langer R, Vacanti J, editor. Principles of Tissue Engineering. 4th ed. London: Academic Press; 2014. 1619-1643
- Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA 2017;318:1861-1862 https://doi.org/10.1001/jama.2017.15218
- Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, Moltu K, Bremnes B, Gronevik E, Muusse M, Hakonsen GD, Skibeli V, Kalland ME, Wang I, Buajordet I, Urbaniak A, Johnston J, Rantell K, Kerwash E, Schuessler-Lenz M, Salmonson T, Bergh J, Gisselbrecht C, Tzogani K, Papadouli I, Pignatti F. The European Medicines Agency review of kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-Cell lymphoma. Oncologist 2020;25:e321-e327 https://doi.org/10.1634/theoncologist.2019-0233
- Patel S, Burga RA, Powell AB, Chorvinsky EA, Hoq N, McCormack SE, Van Pelt SN, Hanley PJ, Cruz CRY. Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer. Front Oncol 2019;9:196
- Upadhaya S, Yu JX, Shah M, Correa D, Partridge T, Campbell J. The clinical pipeline for cancer cell therapies. Nat Rev Drug Discov 2021;20:503-504 https://doi.org/10.1038/d41573-021-00100-z
- Roselli E, Faramand R, Davila ML. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. J Clin Invest 2021;131:e142030
- Jo Y, Ali LA, Shim JA, Lee BH, Hong C. Innovative CAR-T cell therapy for solid tumor; current duel between CAR-T spear and tumor shield. Cancers (Basel) 2020;12:2087
- Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis Markers 2019;2019:3425291
- Townsend MH, Bennion K, Robison RA, O'Neill KL. Paving the way towards universal treatment with allogenic T cells. Immunol Res 2020;68:63-70 https://doi.org/10.1007/s12026-020-09119-7
- Alnaggar M, Xu Y, Li J, He J, Chen J, Li M, Wu Q, Lin L, Liang Y, Wang X, Li J, Hu Y, Chen Y, Xu K, Wu Y, Yin Z. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J Immunother Cancer 2019;7:36
- Deinsberger J, Reisinger D, Weber B. Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. NPJ Regen Med 2020;5:15
- Borlongan CV. Concise review: stem cell therapy for stroke patients: are we there yet? Stem Cells Transl Med 2019;8:983-988 https://doi.org/10.1002/sctm.19-0076
- Kawabori M, Shichinohe H, Kuroda S, Houkin K. Clinical trials of stem cell therapy for cerebral ischemic stroke. Int J Mol Sci 2020;21:7380
- Lalu MM, Mazzarello S, Zlepnig J, Dong YYR, Montroy J, McIntyre L, Devereaux PJ, Stewart DJ, David Mazer C, Barron CC, McIsaac DI, Fergusson DA. Safety and efficacy of adult stem cell therapy for acute myocardial infarction and ischemic heart failure (SafeCell Heart): a systematic review and meta-analysis. Stem Cells Transl Med 2018;7:857-866 https://doi.org/10.1002/sctm.18-0120
- Barker RA, Carpenter MK, Forbes S, Goldman SA, Jamieson C, Murry CE, Takahashi J, Weir G. The challenges of first-in-human stem cell clinical trials: what does this mean for ethics and institutional review boards? Stem Cell Reports 2018;10:1429-1431 https://doi.org/10.1016/j.stemcr.2018.04.010
- Center for Biologics Evaluation and Research, US FDA. Considerations for the design of early-phase clinical trials of cellular and gene therapy products; guidance for industry. Silver Spring: FDA; 2015.
- Center for Biologics Evaluation and Research, US FDA. Guidance for FDA reviewers and sponsors: content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs). Rockville: FDA; 2015.
- Geigert J. An effective CMC strategy is possible. In: Geigert J, editor. The challenge of CMC regulatory compliance for biopharmaceuticals. Cham: Springer; 2019. 53-87
- Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM, Freitas CS, Marcon R, Calixto JB. Non-clinical studies in the process of new drug development - Part II: good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz J Med Biol Res 2016;49:e5646
- Steinmetz KL, Spack EG. The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol 2009;9(Suppl 1):S2
- Senderowicz AM. Information needed to conduct first-inhuman oncology trials in the United States: a view from a former FDA medical reviewer. Clin Cancer Res 2010;16:1719-1725 https://doi.org/10.1158/1078-0432.CCR-09-2766
- Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 2009;24:16-24 https://doi.org/10.2133/dmpk.24.16
- Lee W, Cai Y, Lim TP, Teo J, Chua SC, Kwa AL. In vitro pharmacodynamics and PK/PD in animals. Adv Exp Med Biol 2019;1145:105-116 https://doi.org/10.1007/978-3-030-16373-0_8
- Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, Brendler-Schwaab S, Cirit M, David R, Dehne EM, Durieux I, Ewart L, Fitzpatrick SC, Frey O, Fuchs F, Griffith LG, Hamilton GA, Hartung T, Hoeng J, Hogberg H, Hughes DJ, Ingber DE, Iskandar A, Kanamori T, Kojima H, Kuehnl J, Leist M, Li B, Loskill P, Mendrick DL, Neumann T, Pallocca G, Rusyn I, Smirnova L, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tsyb S, Trapecar M, Van de Water B, Van den Eijnden-van Raaij J, Vulto P, Watanabe K, Wolf A, Zhou X, Roth A. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX 2020;37:365-394
- Kopec AK, Yokokawa R, Khan N, Horii I, Finley JE, Bono CP, Donovan C, Roy J, Harney J, Burdick AD, Jessen B, Lu S, Collinge M, Sadeghian RB, Derzi M, Tomlinson L, Burkhardt JE. Microphysiological systems in early stage drug development: perspectives on current applications and future impact. J Toxicol Sci 2021;46:99-114 https://doi.org/10.2131/jts.46.99
- ICH Guideline M3 (R2) on Non-clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals [Internet]. London: European Medicines Agency; 2009 Dec [cited 2019 Mar 24]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m3r2-non-clinical-safety-studies-conduct-human-clinical-trials-marketing-authorisation_en.pdf.
- Settiagounder N. Histopathology evaluation and peer review for nonclinical studies: raw data compliance to GLP quality systems. J Regul Sci 2017;5:45-55 https://doi.org/10.21423/JRS-V05N02P045
- Food and Drug Administration. Summary basis for regulatory action for idecabtagene vicleucel. Silver Spring: FDA; 2021.
- European Medicines Agency. Assessment report for Alofisel. London: European Medicines Agency; 2017.
- European Medicines Agency. Assessment report for Yescarta. London: European Medicines Agency; 2018.
- Food and Drug Administration. Draft Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Availability. Rockville: FDA; 2013.
- Food and Drug Administration. Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs). Rockville: FDA; 2020.